GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioCorRx Inc (OTCPK:BICX) » Definitions » Forward Rate of Return (Yacktman) %

BioCorRx (BioCorRx) Forward Rate of Return (Yacktman) % : 0.00% (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is BioCorRx Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. BioCorRx's forward rate of return for was 0.00%.

The historical rank and industry rank for BioCorRx's Forward Rate of Return (Yacktman) % or its related term are showing as below:

During the past 13 years, BioCorRx's highest Forward Rate of Return was 20.00. The lowest was -296.28. And the median was -64.97.

BICX's Forward Rate of Return (Yacktman) % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 15.23
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


BioCorRx Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for BioCorRx's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCorRx Forward Rate of Return (Yacktman) % Chart

BioCorRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCorRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCorRx's Forward Rate of Return (Yacktman) %

For the Medical Care Facilities subindustry, BioCorRx's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCorRx's Forward Rate of Return (Yacktman) % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where BioCorRx's Forward Rate of Return (Yacktman) % falls into.



BioCorRx Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

BioCorRx's Forward Rate of Return of Dec. 2023 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/0.78+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCorRx  (OTCPK:BICX) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


BioCorRx Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of BioCorRx's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCorRx (BioCorRx) Business Description

Traded in Other Exchanges
N/A
Address
2390 East Orangewood Avenue, Suite 500, Anaheim, CA, USA, 92806
BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application.
Executives
Louis C. Lucido director 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Joseph J Galligan director, 10 percent owner 333 SOUTH GRAND AVENUE, 18TH FLOOR, LOS ANGELES CA 90071
Harsha Murthy director 5209 38TH STREET,NW, WASHINGTON DC 20015
Luisa Ingargiola director 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
Thomas Patrick Welch officer: Vice President of Operations 10453 SARAH ST., TOLUCA LAKE CA 91602
Kent Emry director, officer: Chief Executive Officer 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Brady James Granier director 13024 DELANO STREET, VALLEY GLEN CA 91401
Lourdes Felix director, officer: Chief Financial Officer 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
Jorge Jr Andrade director, officer: Chief Executive Officer PO BOX 5366, SANTA ANA CA 92704
Muller Neil Terrence Mr director, officer: President 13231 SANDHURST PLACE, SANTA ANA CA 92705

BioCorRx (BioCorRx) Headlines

From GuruFocus

BioCorRx Provides Business Update for the First Quarter of 2023

By sperokesalga sperokesalga 05-16-2023

BioCorRx Featured on LiveNOW from FOX

By GuruFocusNews GuruFocusNews 06-27-2022

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors

By Stock market mentor Stock market mentor 01-24-2023